Filings & corporate actions
78 results filed
CSVNext results · Q2 FY27
Expected 8 Nov 2026 – 12 Nov 2026
Estimate: filed 39–43 days after quarter end, last 5 times
Dividend
₹0.40 per share · last 22 Sept 2026
2026
- 22 SeptdividendDividend · ₹0.40 per share+3.6%
- 31 JulresultsResults · Q1 FY27 · consolidated and standalone-2.8%NSE
- 10 JulshareholdingShareholding · 30 Jun 2026-1.1%NSE
- 22 MayresultsResults · Q4 FY26 · consolidated and standalone-3.2%NSE
- 16 AprshareholdingShareholding · 31 Mar 2026-3.2%NSE
- 7 FebresultsResults · Q3 FY26 · consolidated and standalone+0.7%NSE
- 9 JanshareholdingShareholding · 31 Dec 2025-1.3%NSE
Reaction to results · all yearsrose on day 0 in 33 of 78 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 31 Jul 2026 | -2.8% | -0.5% | -0.5% | 1.4× |
| Q4 FY26 | 22 May 2026 | -3.2% | -4.6% | -0.3% | 2.6× |
| Q3 FY26 | 7 Feb 2026 | +0.7% | +7.0% | +32.2% | 2.4× |
| Q2 FY26 | 8 Nov 2025 | +1.3% | +0.3% | +10.6% | 34.1× |
| Q1 FY26 | 9 Aug 2025 | +2.4% | +6.4% | +19.5% | 2.0× |
| Q4 FY25 | 30 May 2025 | -1.8% | -5.5% | -5.3% | 2.2× |
| Q3 FY25 | 12 Feb 2025 | -3.1% | -3.8% | -10.6% | 1.8× |
| Q2 FY25 | 8 Nov 2024 | -5.0% | -15.3% | -14.4% | 1.6× |
| Q1 FY25 | 5 Aug 2024 | -9.9% | -9.7% | +9.9% | 2.3× |
| Q4 FY24 | 29 May 2024 | -6.1% | -7.0% | +5.5% | 2.7× |
| Q3 FY24 | 8 Feb 2024 | +11.9% | +14.0% | +36.8% | 44.3× |
| Q2 FY24 | 8 Nov 2023 | -2.1% | -2.4% | -2.8% | 1.4× |
| Q1 FY24 | 8 Aug 2023 | +3.1% | +2.0% | +1.0% | 1.8× |
| Q4 FY23 | 24 May 2023 | +0.9% | 0.0% | +10.0% | 1.6× |
| Q3 FY23 | 9 Feb 2023 | +3.6% | -4.6% | -5.2% | 5.5× |
| Q2 FY23 | 12 Nov 2022 | -13.9% | -22.0% | -20.8% | 5.8× |
| Q1 FY23 | 13 Aug 2022 | -6.2% | -8.1% | +5.2% | 4.4× |
| Q4 FY22 | 30 May 2022 | -3.1% | -1.0% | -3.4% | 3.4× |
| Q3 FY22 | 9 Feb 2022 | -4.6% | -10.9% | -16.7% | 1.2× |
| Q2 FY22 | 12 Nov 2021 | -1.9% | -4.8% | -9.1% | 2.2× |
| Q1 FY22 | 7 Aug 2021 | -3.3% | -7.2% | -14.1% | 1.1× |
| Q4 FY21 | 30 May 2021 | +0.8% | -3.8% | +5.8% | 1.4× |
| Q3 FY21 | 11 Feb 2021 | +3.5% | +0.2% | 0.0% | 3.1× |
| Q2 FY21 | 4 Nov 2020 | -1.8% | +2.4% | +14.8% | 0.5× |
| Q1 FY21 | 12 Aug 2020 | +2.6% | -3.6% | -12.6% | 0.7× |
| Q4 FY20 | 6 Jun 2020 | -1.4% | +26.4% | +44.4% | 3.3× |
| Q3 FY20 | 13 Feb 2020 | -3.6% | -5.3% | -27.2% | 1.6× |
| Q2 FY20 | 13 Nov 2019 | +3.2% | +1.9% | -0.1% | 2.3× |
| Q1 FY20 | 13 Aug 2019 | -1.8% | -5.9% | +4.2% | 1.6× |
| Q4 FY19 | 28 May 2019 | +3.4% | -0.9% | -9.4% | 6.3× |
| Q3 FY19 | 28 Feb 2019 | +0.3% | +3.0% | -0.2% | 1.4× |
| Q2 FY19 | 22 Nov 2018 | +0.4% | +0.1% | -4.0% | 0.5× |
| Q1 FY19 | 2 Aug 2018 | +2.0% | -4.2% | +11.7% | 1.7× |
| Q4 FY18 | 21 Jun 2018 | -1.7% | -1.4% | -11.2% | 0.2× |
| Q3 FY18 | 22 Feb 2018 | -0.6% | -3.6% | -17.6% | 0.6× |
| Q2 FY18 | 18 Dec 2017 | +0.6% | +3.2% | +1.6% | 0.4× |
| Q1 FY18 | 21 Sept 2017 | +0.4% | -4.2% | -7.2% | 10.0× |
| Q4 FY17 | 10 Jun 2017 | +0.4% | +1.7% | +2.6% | 0.3× |
| Q3 FY17 | 13 Feb 2017 | -1.4% | -3.2% | -6.2% | 0.5× |
| Q2 FY17 | 7 Nov 2016 | +2.4% | -10.0% | -6.5% | 0.6× |
| Q1 FY17 | 13 Aug 2016 | -2.1% | +3.7% | +2.4% | 0.2× |
| Q4 FY16 | 16 May 2016 | +0.9% | -5.2% | +1.9% | 0.8× |
| Q3 FY16 | 12 Feb 2016 | +1.3% | -4.4% | +5.5% | 1.1× |
| Q2 FY16 | 9 Nov 2015 | -0.3% | +3.0% | +14.1% | 0.6× |
| Q1 FY16 | 11 Aug 2015 | -6.3% | -5.1% | -19.1% | 1.2× |
| Q4 FY15 | 4 Jun 2015 | -0.6% | -0.7% | +6.3% | 0.6× |
| Q3 FY15 | 10 Feb 2015 | +0.7% | +2.1% | +11.8% | 0.5× |
| Q2 FY15 | 18 Nov 2014 | -0.6% | -5.5% | -9.4% | 0.7× |
| Q1 FY15 | 14 Aug 2014 | +0.7% | -1.2% | +26.1% | 1.2× |
| Q4 FY14 | 7 Jun 2014 | +0.5% | -3.1% | +24.7% | 0.9× |
| Q3 FY14 | 12 Feb 2014 | +4.6% | +15.6% | +16.8% | 0.4× |
| Q2 FY14 | 22 Nov 2013 | -1.8% | -4.8% | +16.7% | 0.1× |
| Q1 FY14 | 19 Aug 2013 | -3.3% | -8.8% | -3.6% | 0.0× |
| Q4 FY13 | 20 Jun 2013 | -10.4% | -10.8% | -17.7% | 3.4× |
| Q3 FY13 | 20 Feb 2013 | +0.7% | +8.4% | -3.1% | 2.6× |
| Q2 FY13 | 16 Nov 2012 | +0.5% | +1.6% | -0.5% | 0.0× |
| Q1 FY13 | 13 Aug 2012 | -0.3% | +4.7% | +4.4% | 0.2× |
| Q4 FY12 | 11 May 2012 | -4.7% | -6.3% | -10.3% | 0.4× |
| Q3 FY12 | 20 Feb 2012 | -0.6% | +0.3% | -9.1% | 2.0× |
| Q2 FY12 | 2 Nov 2011 | +0.3% | +0.9% | -8.5% | 1.5× |
| Q1 FY12 | 8 Aug 2011 | -7.1% | -7.4% | -13.2% | 0.6× |
| Q4 FY11 | 12 May 2011 | -1.0% | -1.0% | +4.1% | 0.3× |
| Q3 FY11 | 29 Jan 2011 | -0.8% | -0.5% | -3.7% | 0.4× |
| Q2 FY11 | 1 Nov 2010 | +0.5% | +2.4% | +3.4% | 0.9× |
| Q1 FY11 | 23 Jul 2010 | -0.3% | +3.6% | +11.4% | 3.1× |
| Q4 FY10 | 12 May 2010 | +0.6% | -2.6% | -2.9% | 0.2× |
| Q3 FY10 | 30 Jan 2010 | +1.0% | 0.0% | +5.9% | 0.4× |
| Q2 FY10 | 28 Oct 2009 | -2.8% | -3.5% | -5.2% | 0.1× |
| Q1 FY10 | 25 Jul 2009 | -3.5% | +0.4% | +8.8% | 0.5× |
| Q4 FY09 | 30 Apr 2009 | 0.0% | +0.5% | +55.4% | 9.9× |
| Q3 FY09 | 27 Jan 2009 | -2.0% | +0.7% | -2.0% | 0.3× |
| Q2 FY09 | 1 Nov 2008 | -3.3% | -2.9% | -25.4% | 1.5× |
| Q1 FY09 | 30 Jul 2008 | -0.4% | -1.8% | -6.3% | 3.1× |
| Q4 FY08 | 30 Apr 2008 | +3.1% | +11.7% | +36.1% | 1.5× |
| Q3 FY08 | 31 Jan 2008 | -2.0% | -3.6% | -9.9% | 0.4× |
| Q2 FY08 | 29 Oct 2007 | -1.4% | -2.8% | -2.0% | 1.5× |
| Q1 FY08 | 30 Jul 2007 | -3.3% | -8.7% | -13.4% | 3.5× |
| Q4 FY07 | 30 Apr 2007 | +1.9% | +8.4% | +5.6% | 0.9× |
| Average | -1.0% | -1.4% | +1.4% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+5.6%
Profit YoY+2.0%
Interest cost YoY—
Revenue QoQ-13.0%
Profit QoQ-36.1%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen479.95
Day range467.55 – 482.80
52-week range242.25 – 494.45
From 52w high-4.5%
RSI (14)62.2
ATR (14)21.58
Volume2.43L
Avg volume (20D)15.94L
Rel volume0.15×
Volatility (1Y)48.3%
Turnover₹11.5Cr
SMA 50 / 200400.42 / 378.29
Delivery percentage
Latest · 6 Oct 202646.5%
20-day avg35.7%
1-year avg41.8%
Percentile (own history)33rd
Range8.4–98.5%
Sessions1,731
Over the last 20 sessions SMSPHARMA settled 35.7% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 41.8%, so recent sessions are running 6.1 points lower than usual. The latest session ranks higher than 33% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -1.18% | +2.17% | +26.21% | +11.50% | +21.62% | +87.62% |
Valuation
CSVMarket cap₹4,422 Cr
P/E (TTM)43.2
EPS (TTM)10.93
Shares outstanding9.37Cr
Listed28 Feb 2007
Ownership
CSVPromoter68.07%
Promoter Δ QoQ0.00 pp
Public31.93%
FII0.65%
DII2.83%
Pledged17.99%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 242.4 | 210.4 | 237.9 | 207.0 |
| YoY chg | — | — | -4.1% | +5.6% |
| Net profit (₹ Cr) | 25.3 | 23.5 | 32.7 | 20.9 |
| YoY chg | — | — | +61.0% | +2.0% |
| Net margin | 10.4% | 11.2% | 13.7% | 10.1% |
| EPS | 2.84 | 2.59 | 3.58 | 2.23 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 68.07% · public 31.93%2019-092026-06
- Promoter
- Public and others
- Promoter
- 68.07%
- Public
- 31.93%
- Promoter change
- 0.00 pp
- Filed
- 10 Jul 2026
- FII
- 0.65%
- DII
- 2.83%
- Promoter pledged
- 17.99%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 166.6 | 161.5 | 245.8 | 164.5 | 196.7 | 173.4 | 248.2 | 196.0 | 242.4 | 210.4 | 237.9 | 207.0 | |
| Other income | 0.8 | 1.5 | 1.6 | 1.4 | 1.3 | 2.1 | 1.4 | 0.6 | 1.4 | 3.8 | 2.6 | 1.7 | |
| Total income | 167.5 | 163.0 | 247.4 | 165.8 | 198.1 | 175.5 | 249.6 | 196.6 | 243.9 | 214.2 | 240.5 | 208.7 | |
| Total expenses | 152.3 | 146.4 | 225.7 | 144.0 | 178.5 | 153.0 | 221.1 | 172.3 | 209.8 | 183.0 | 213.5 | 181.5 | |
| └ Finance costs | 5.6 | 6.0 | 5.6 | 4.7 | 4.6 | 4.2 | 5.1 | 5.8 | 5.7 | 6.2 | 5.3 | 5.5 | |
| └ Depreciation | 7.9 | 8.0 | 7.9 | 8.4 | 8.6 | 8.7 | 8.6 | 9.8 | 10.0 | 10.0 | 10.1 | 10.0 | |
| Profit before tax | 15.2 | 16.5 | 21.7 | 21.8 | 19.5 | 22.4 | 28.5 | 24.4 | 34.0 | 31.2 | 27.1 | 27.2 | |
| Tax expense | 3.1 | 4.2 | 5.7 | 5.5 | 5.7 | 5.4 | 8.4 | 5.7 | 8.9 | 8.0 | 6.1 | 7.0 | |
| Net profit | 11.7 | 11.5 | 17.3 | 16.5 | 14.1 | 18.2 | 20.3 | 20.5 | 25.3 | 23.5 | 32.7 | 20.9 | |
| EPS | 1.39 | 1.36 | 2.04 | 1.95 | 1.69 | 2.15 | 2.40 | 2.31 | 2.84 | 2.59 | 3.58 | 2.23 | |
| Net margin | 7.04% | 7.11% | 7.03% | 10.02% | 7.17% | 10.52% | 8.18% | 10.45% | 10.44% | 11.15% | 13.75% | 10.10% | |
| PBT margin | 9.10% | 10.23% | 8.84% | 13.27% | 9.93% | 12.94% | 11.49% | 12.43% | 14.04% | 14.81% | 11.38% | 13.14% | |
| Tax rate | 20.53% | 25.63% | 26.15% | 24.99% | 29.07% | 23.89% | 29.60% | 23.20% | 26.18% | 25.58% | 22.55% | 25.75% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 31 Jul 2026.
SMSPHARMA at a glance
- SMSPHARMA closed at ₹472.2 on 6 Oct 2026, -1.18% on the day, +87.6% over one year, 4.5% below its 52-week high of ₹494.45.
- Delivery was 46.5% of traded quantity on 6 Oct 2026, the 33rd percentile of its own 1,731 sessions with a reading (20-session average 35.7%, 1-year average 41.8%).
- Market capitalisation is ₹4,422 crore at a trailing P/E of 43.2 (trailing EPS ₹10.93).
- Q1 FY27 results (consolidated, filed 31 Jul 2026): revenue ₹207 crore (+5.6% year on year), net profit ₹21 crore (+2.0%); the price moved -2.8% on the first session after.
- Promoters held 68.07% at 30 Jun 2026, unchanged on the previous filing, with 17.99% of promoter shares pledged.
- Q2 FY27 results are expected between 8 Nov 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE812G01025
SeriesEQ
Listed28 Feb 2007
History from28 Feb 2007
Sessions4,825
Turnover rank#394
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE